Program
Inactivated Hepatitis A Vaccine (Human Diploid Cell) (1 mL)
Also written as “Inactivated Hepatitis A Vaccine (Human Diploid Cell) (0.5 mL)”.
Its studies are mostly in Hepatitis, led by Sinovac Biotech.
Furthest: phase 3, since Aug 25, 20261 company-led study, 1 open or runningNext primary completion: Sep 15, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sinovac Biotech | 11 open or running | phase 3since Aug 25, 2026 | Aug 25, 2026 | Sep 15, 2027phase 3 · NCT07793227 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 25, 2026First study: phase 3 study in HepatitisFirst studyNCT07793227 · 680 planned · Vietnam
Ahead
- Sep 15, 2027Primary completion: phase 3 study in HepatitisNCT07793227
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Inactivated Hepatitis A Vaccine (Human Diploid Cell) (1 mL)”name, by rule
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07793227Hepatitis · Vietnam | 3 | Recruiting | Sep 15, 2027 | 680 |
How it is read
Names in the registry
- “Inactivated Hepatitis A Vaccine (Human Diploid Cell) (1 mL)”, 1 entry
- “Inactivated Hepatitis A Vaccine (Human Diploid Cell) (0.5 mL)”, 1 entry
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.